



British Association for
Community Child Health

Virtual Annual Scientific Meeting

9-10 November 2020

All registered delegates were emailed details of how to access the meeting on 4 November: please contact bacch@rcpch.ac.uk if you have not received this message.

Day 1: Monday 9 November (afternoon)

Timings	Description
13.30-13.40	Virtual welcome from BACCH Deputy Academic Convenor Dr Jo Garstang (and waiting for all delegates to join)
13.40-14.20*	<i>Child Safeguarding Practice Reviews: how serious are we about learning from serious & fatal child maltreatment?</i> Dr Peter Sidebotham (Emeritus Professor of Child Health, Univ. of Warwick)
14.20-15.00*	<i>Implication of rapid whole genome sequencing for children with neurodevelopmental disorders</i> Professor Lucy Raymond (Professor of Medical Genetics & Neurodevelopment, Department of Medical Genetics, University of Cambridge)
15.00-15.10	Break
15.10-15.15	Welcome back
15.15-15.55*	<i>Challenging behavioural problems in conduct & neurodevelopmental disorders – what behavioural support/program is available for children and families?</i> Professor Angela Hassiotis (Professor of Psychiatry of Intellectual Disability, University College London and Camden & Islington Foundation NHS Trust)
15.55-16.00	End of day one round up from BACCH Deputy Academic Convenor

Day 2: Tuesday 10 November (morning)

Timings	Description
09.10-09.30	<i>AGM – BACCH Members only (separate meeting)</i>
10.00-10.10	Virtual welcome from BACCH Academic Convenor Dr Alice Setti (and waiting for all delegates to join)
10.10-10.50*	<i>BACCH Improving Services Series</i> Dr Lisa Kauffmann (BACCH Chair) & Dr Simon Lenton (BACAPH Co-Chair)
10.50-11.30*	<i>Implementation of the new Child Death Review statutory guidance - one year on</i> Dr Jo Garstang (Consultant Community Paediatrician & Designated Doctor for Unexpected Child Deaths, Birmingham Community NHS Trust)
11.30-11.40	Break
11.40-11.45	Welcome back
11.45-12.25*	<i>Prevalence, presentation and treatment of anxiety in autism</i> Dr Ann Ozsivadjian (Principal Clinical Psychologist Independent practice and King's College London (Honorary))
12.25-12.30	End of meeting round up from BACCH Academic Convenor

*including 10 minutes for questions from delegates

Welcome to the Annual Scientific Meeting (ASM) of the British Association for Community Child Health (BACCH). When I took up post in 2017 as the Deputy Academic Convenor, little would I have known that my four-year tenure would be riddled with such surprises and that I would be the first BACCH Academic Convenor in history to be delivering the ASM in a pandemic.

Though it is unfortunate that we do not have the privilege of physically gathering and attending a two full day event, we are grateful for the technology that enables us to keep up and quench the thirst for knowledge. But what cannot be replaced by any means is our practice of gathering together for the feast at the Annual Dinner times – a BACCH tradition - and this will be sorely missed, you will agree. Keeping the DSE (Display Screen Equipment) regulations in mind and after much thought, we decided to condense this ASM to two half days.

Much effort has gone into organising this meeting and I hope that you would find this a highly valuable experience and a good investment of your time and hard earned money.

I would like to thank the Speakers for sharing their wealth of knowledge and expertise.

Thanks to our Chair Dr Lisa Kauffmann and all members of our BACCH Executive Committee for their valuable suggestions on topics in getting this event together. My special thanks as always to the extremely efficient BACCH administration team staff - Isabelle Robinson (Executive Officer) and Prafula Bhadeshia (Assistant Administrator).

Finally, it goes without saying that all these academic events are being made possible entirely only due to your ongoing support to BACCH as members. Keep reading our BACCH newsletters that strive to bring you the latest information. Have a great year till the next ASM.

Thank you so much.

Alice S

Dr Alice Christa Bella Setti. MBBS FRCPCH
BACCH Academic Convenor

#BACCH2020

Child Safeguarding Practice Reviews: how serious are we about learning from serious & fatal child maltreatment?

Dr Peter Sidebotham (Emeritus Professor of Child Health, University of Warwick)

Synopsis

While overall rates of fatal child abuse have fallen over the years, children in our country continue to suffer serious and fatal harm as a result of abuse and neglect. It is all too easy to point the finger of blame either at the parents, or at the professionals working with these families. The reality, though, is that children will continue to suffer in spite of all the good work that is done to protect them and to promote their welfare. We owe it to these children to learn the lessons from serious and fatal child maltreatment and to strive – both individually and corporately – to improve our services for children and families.

Drawing on the national analyses of serious case reviews and the work of the national child safeguarding practice review panel, this lecture will explore some of the key learning to come out of recent reviews and their relevance to paediatricians and other professionals.

Biography

Peter Sidebotham is a retired paediatrician and emeritus Professor of child health at the University of Warwick. As an academic paediatrician he specialised in child protection and was the designated doctor for child protection and for child death review in Warwickshire.

Peter's research includes studies on unexpected child deaths including sudden infant death syndrome, and work on child death review and child maltreatment. He has worked with Professor Marian Brandon from UEA on several national analyses of Serious Case Reviews. He is the author/editor of three books and several book chapters and has published extensively on child abuse and child death review.

Peter is a co-editor of the journal Child Abuse Review. He is on the Boards of Trustees for the Association of Child Protection Professionals and the Lullaby Trust and is a member of the National Child Safeguarding Practice Review Panel.

Implication of rapid whole genome sequencing for children with neurodevelopmental disorders

Professor Lucy Raymond (Professor of Medical Genetics & Neurodevelopment, Department of Medical Genetics, University of Cambridge)

Synopsis

Our ability to provide genetic testing has dramatically changed in the last five years. Not only can the whole genome be interrogated as a single test but also results can be delivered to the bedside within 2-3 weeks. The talk will be illustrated with results from the Next Generation Children Project led in Cambridge over the past three years. This approach is now being offered through the NHS to PICU and NICU nationally. Rapid diagnosis has huge implications for community paediatrics as many children will have a genetic diagnosis earlier in their life course. The advantages and considerations needed with a genomics first approach will be discussed. New opportunities for personalised medicine are available with an early diagnosis and the need for more post diagnosis follow up and support are discussed.

Biography

Lucy Raymond is Professor of Medical Genetics and Neurodevelopment at the University of Cambridge and Honorary Consultant in Medical Genetics at Cambridge University Hospital, Cambridge Biomedical Campus, UK. Her research interest is understanding the genetic basis of intellectual disability and has identified many disease causing genes over the years which have been rapidly translated into clinical service. She leads several collaborative efforts to identify rare disease genes including the 100,000 Genome Project and rapid diagnosis in NICU and PICU

Challenging behavioural problems in conduct & neurodevelopmental disorders – what behavioural support/program is available for children and families?

Professor Angela Hassiotis (Professor of Psychiatry of Intellectual Disability, University College London and Camden & Islington Foundation NHS Trust)

Synopsis

The lecture will concentrate on raising awareness of behaviour problems in children and young people with developmental delay, on interventions that may alleviate the problems and what should professionals and parents should do to receive prompt support.

The talk will briefly mention the EPICC-ID randomised controlled trial which is testing Stepping Stones Triple P in preschool children with moderate to severe developmental delay.

Biography

Angela Hassiotis is Professor of Psychiatry of Intellectual Disability at UCL (Division of Psychiatry, Faculty of Brain Sciences) and Consultant Psychiatrist at the Camden Learning Disability Service/Camden and Islington Foundation Trust in central London. Angela is a strong advocate of evidence-based care and her main research interest is in developing, adapting and evaluating interventions for people with intellectual disabilities and mental disorders across the lifespan. She has published extensively and has developed close collaborations with experts by experience and their family carers in her research. She is currently leading on a five year NIHR funded programme on aggression. She has served in the Faculty of the Psychiatry of Intellectual Disability executive, IASSIDD Council and the IASSIDD Academy, NICE guideline Development Groups, NIHR Funding boards, various research advisory committees, the editorial board of Lancet Psychiatry, Editor in Chief of the Journal of Mental Health Research in Intellectual Disabilities and Equality Diversity and Inclusion Lead for the Division of Psychiatry.


Paediatric Licensed medicine – Sialanar®


(400mcg/ml glycopyrronium bromide equivalent to 320mcg/ml glycopyrronium)





Sialanar® is a liquid form of glycopyrronium bromide developed specifically for children


Benefits of dispensing Sialanar® for patients under your care:


- 

Concentrated solution (2mg/5ml glycopyrronium bromide) therefore relatively small volume to swallow
- 


Raspberry flavouring increases the palatability for the patient
- 

Sugar and Sorbitol free. Designed with minimal excipients
- 

In use shelf life of 60 days
- 

Easy to titrate the dose with the oral dosing syringe and can be used with nasogastric and PEG tubes
- 

Sialanar® requires no further manipulation and is licensed to be administered via feeding tubes



To ensure your patient has Sialanar® dispensed when you prescribe it, it is important you write the prescription as follows:
Glycopyrronium bromide oral solution 400mcg/ml (Sialanar®) or Sialanar® oral solution

Prescribing Information UK

Sialanar® 320 micrograms /ml oral solution

Please refer to the full Summary of Product Characteristics (SmPC) before prescribing.

Presentation: Glycopyrronium oral solution in 250 ml or 60 ml bottle. 1 ml solution contains 400 micrograms glycopyrronium bromide, (equivalent to 320 micrograms of the active ingredient, glycopyrronium).

Indication: Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.

Dosage: Start with approximately 12.8 micrograms/kg body weight of glycopyrronium per dose, three times per day. Increase dose weekly until efficacy is balanced with side effects. Titrate to maximum individual dose of 64 mcg/kg body weight glycopyrronium or 6 ml three times a day, whichever is less. Monitor at least 3 monthly for changes in efficacy and/or tolerability and adjust dose if needed. Not for patients less than 3 or over 17 years old as Sialanar® is indicated for the paediatric population only. Reduce dose by 30% in mild/moderate renal failure. Dose at least one hour before or two hours after meals or at consistent times with respect to food intake. Avoid high fat food. Flush nasogastric tubes with 10 ml water.

Contraindications: Hypersensitivity to active substance or excipients; pregnancy and breast-feeding; glaucoma; urinary retention; severe renal impairment/dialysis; history of intestinal obstruction, ulcerative colitis, paralytic ileus, pyloric stenosis; myasthenia gravis; concomitant treatment with potassium chloride solid oral dose or anticholinergic drugs.

Special warnings and precautions for use: Monitor anticholinergic effects. Carer should stop treatment and seek advice in the event of constipation, urinary retention, pneumonia, allergic reaction, pyrexia, very hot weather or changes in behaviour. For continuous or repeated intermittent treatment, consider benefits and risks on case-by-case basis. Not for mild to moderate sialorrhoea. Use with caution in cardiac disorders; gastro-oesophageal reflux disease; pre-existing constipation or diarrhoea; compromised blood brain barrier; in combination with: antispasmodics, topiramate, sedating antihistamines, neuroleptics/

antipsychotics, skeletal muscle relaxants, tricyclic antidepressants and MAOIs, opioids or corticosteroids. Sialanar® contains 2.3 mg sodium benzoate (E211) in each ml. Patients require daily dental hygiene and regular dental checks. Thicker secretions may increase risk of respiratory infection and pneumonia. Moderate influence on ability to drive/use machines.

Fertility, pregnancy and lactation: Use effective contraception. Contraindicated in pregnancy and breast feeding.

Undesirable effects: Adverse reactions more common with higher doses and prolonged use. In placebo-controlled studies (≥15%) dry mouth, constipation, diarrhoea and vomiting, urinary retention, flushing and nasal congestion. In paediatric literature; very common: irritability, reduced bronchial secretions; common: upper respiratory tract infection, pneumonia, urinary tract infection, agitation, drowsiness, epistaxis, rash, pyrexia. The Summary of Product Characteristics should be consulted for a full list of side effects.

Shelf life: 2 years unopened. 2 months after first opening.

MA number:
 Sialanar® 250 ml bottle – EU/1/16/1135/001
 Sialanar® 60ml Bottle – EU/1/16/1135/002

Legal Category: POM

Basic NHS Price:
 Sialanar® 250 ml bottle £320
 Sialanar® 60ml bottle £76.80

Marketing Authorisation Holder (MAH):
 Proveca Pharma Ltd, Marine House,
 Clanwilliam Place, Dublin 2, Ireland
 Further prescribing information can be obtained from the MAH.

Date of last revision of prescribing information: April 2019

UK-SIA-2020-097

Date of preparation: November 2020

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard

Adverse events should also be reported to Proveca Limited. Phone: 0333 200 1866 E-mail: medinfo@proveca.co.uk

BACCH Improving Services Series

Dr Lisa Kauffmann (BACCH Chair) & **Dr Simon Lenton** (BACAPH Co-Chair)

Synopsis

The 2020 NHS Long-Term Plan signals a significant change of direction away from the previous more market orientated reforms of recent years.

Central to new ways of working are the design and delivery of patient orientated services based on pathways and networks which integrate quality improvement. The plan introduces population health management and the need to integrate prevention and reduce inequitable outcomes. The Plan also recognises the importance of value, reducing unnecessary appointments, looking after NHS staff and the need to introduce new ways of working. Clinicians will have leadership roles in Integrated Health Systems and the expectation is that there will be greater integration particularly between community and primary care serves to create comprehensive services around families.

To help paediatricians to improve their services BACCH is launching a series of mini-modules covering the important aspects of the NHS Long Term Plan entitled the Improving Services Series.

Biographies

Simon Lenton is a retired Consultant Community Paediatrician. He is a past Policy Adviser at the Department of Health, past Vice President of RCPCH and past Chair of BACCH. He is currently Co-Chair of the British Association for Child & Adolescent Child Health (BACAPH).

Following the most rewarding and satisfying career possible, Lisa Kauffmann retired from her post as consultant community paediatrician in August 2020. She has also held multiple leadership roles, including associate Medical Director in her Trust, and Chair of the RCPCH PiMM Committee, and RCPCH Honorary Treasurer. She also has the pleasure of continuing to chair BACCH!

Implementation of the new Child Death Review statutory guidance - one year on

Dr Jo Garstang (Consultant Community Paediatrician, Designated Doctor for Child Death, Birmingham Community Healthcare NHS Trust)

Synopsis

The 2018 Statutory Child Death Review guidance came into effect in October 2019, but many paediatricians have limited understanding of the processes and what they may be required to do. This presentation will outline the CDR process, National Child Mortality Database, explain about CDR meetings for children who die in the community, how community paediatricians should contribute to CDR, and the impact of COVID. To the uninformed CDR may be viewed as a paper-exercise, only relevant for hospital deaths and with limited meaning for families and services. But, no child should die prematurely, it is only by investigating deaths thoroughly that we can learn from them, and help prevent future deaths. Children live in the community not in hospitals, so community paediatricians need to be involved.

Biography

Dr Garstang is an academic community paediatrician, and expert in Child Death Review and Sudden Unexpected Death in Infancy (SUDI). Her research has led to improvements in the investigation of SUDI and support for families. She is on the national steering committee for the Care of Next Infant (CONI) programme, and led research on sibling SUDI cases. Dr Garstang has been part of the research team for the last two triennial analyses of Serious Case Reviews. She is the Designated Doctor for Child Death in Birmingham, leading her local SUDI service and establishing a Child Death Review team within the CCG.

Prevalence, presentation and treatment of anxiety in autism

Dr Ann Ozsvadjian (Principal Clinical Psychologist Independent practice and King's College London (Honorary))

Synopsis

Anxiety problems commonly co-occur with Autism Spectrum Disorder (ASD), and yet these problems often go untreated. This can be due to a number of factors including diagnostic overshadowing and difficulty recognising and assessing these problems. There is now good research evidence demonstrating the high prevalence rates – and sometimes atypical phenomenology – of anxiety in ASD, and in recent years a number of randomised controlled trials have been published, primarily using a cognitive-behavioural treatment packages, with promising results.

The talk will focus on identification and treatment of anxiety associated with ASD. As a part of this, we will discuss theoretical knowledge about autistic thinking and processing styles that can predispose young people with ASD to problems of anxiety (and depression), and think about how this knowledge can inform interventions

Biography

For 16 years post-qualification Ann worked at the Evelina London Children's Hospital, in a regional complex neurodisability service where as well as being the lead psychologist for several years, she had a key role in developing intervention services for young people and families with neurodiverse issues. Prior to this she completed her training at Oxford, and prior to that worked at the Michael Rutter Centre, Maudsley Hospital in various research and clinical roles.

As well as being a busy clinician, she is an active researcher. She has particular interests in the cognitive pathways to mental health problems in ASD, and how this knowledge can inform interventions.